ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to MDS
Related studies linked through entity extraction aliases.
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE3
Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes
- Status
- UNKNOWN
- Phase
- PHASE2
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
- Status
- COMPLETED
- Phase
- PHASE3
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Non-interventional Study With Azacitidin (Vidaza®)
- Status
- COMPLETED
- Phase
- N/A
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
- Status
- COMPLETED
- Phase
- PHASE2
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
- Status
- TERMINATED
- Phase
- PHASE1
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
- Status
- COMPLETED
- Phase
- PHASE2
Umbilical Cord Blood Transplant for Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
- Status
- COMPLETED
- Phase
- PHASE3
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE2
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
- Status
- COMPLETED
- Phase
- PHASE1
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
- Status
- UNKNOWN
- Phase
- PHASE2
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
- Status
- COMPLETED
- Phase
- PHASE2